New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 10mg - film coated tablet - 10 mg - active: simvastatin 10mg excipient: ascorbic acid butylated hydroxyanisole carnauba wax citric acid monohydrate hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 20mg - film coated tablet - 20 mg - active: simvastatin 20mg excipient: ascorbic acid butylated hydroxyanisole carnauba wax citric acid monohydrate hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 40mg - film coated tablet - 40 mg - active: simvastatin 40mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate hyprolose hypromellose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 5mg - film coated tablet - 5 mg - active: simvastatin 5mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate hyprolose hypromellose iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - simvastatin 80mg - film coated tablet - 80 mg - active: simvastatin 80mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate hyprolose hypromellose iron oxide red lactose monohydrate magnesium stearate methylated spirits microcrystalline cellulose purified talc purified water   starch titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, lipex is indicated to: · reduce the risk of total mortality by reducing chd deaths; · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures; · reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or chd deaths); · reduce the risk of stroke; · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty); · reduce the need for peripheral and other non-coronary revascularisation procedures; · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, lipex reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers). in hypercholesterolaemic patients with coronary heart disease, lipex slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - rizatriptan benzoate 14.53mg equivalent to 10 mg rizatriptan - wafer - 10 mg - active: rizatriptan benzoate 14.53mg equivalent to 10 mg rizatriptan excipient: aspartame gelatin glycine mannitol mentha x piperita purified water - for the acute treatment of migraine attacks with or without aura.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - montelukast sodium 4.16mg equivalent to 4 mg montelukast free acid - chewable tablet - 4 mg - active: montelukast sodium 4.16mg equivalent to 4 mg montelukast free acid excipient: aspartame cherry flavour 181612 croscarmellose sodium hyprolose iron oxide red magnesium stearate mannitol microcrystalline cellulose purified water - indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and nighttime symptoms and the prevention of exercise-induced bronchospasm.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - montelukast sodium 5.2mg equivalent to 5 mg montelukast free acid - chewable tablet - 5 mg - active: montelukast sodium 5.2mg equivalent to 5 mg montelukast free acid excipient: aspartame cherry flavour 181612 croscarmellose sodium hyprolose iron oxide red magnesium stearate mannitol microcrystalline cellulose - indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and nighttime symptoms and the prevention of exercise-induced bronchospasm.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - montelukast sodium 10.4mg equivalent to 10 mg montelukast free acid - film coated tablet - 10 mg - active: montelukast sodium 10.4mg equivalent to 10 mg montelukast free acid excipient: carnauba wax croscarmellose sodium hyprolose   hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose titanium dioxide - indicated in adults and paediatric patients 2 years of age and older for the relief of daytime and nighttime symptoms of seasonal allergic rhinitis and perennial allergic rhinitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg - capsule - 200 mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 - victrelis (boceprevir) is indicated for the treatment of chronic hepatitis c (hcv) genotype 1 infection, in a combination regimen with peginterferon alpha and ribavirin, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.